Lucid Registry Study (Lucid Registry)
En multicenter, prospektiv, open-label registerundersøgelse af brugen af EsoGuard, på prøver indsamlet ved hjælp af EsoCheck, i en risikobefolkning, der gennemgår standardbehandlingsscreening for og håndtering af tidligere udiagnosticeret Barretts esophagus og/eller esophageal adenocarcinom
This is a multicenter, prospective, observational study designed to capture a limited set of data consisting of diagnostic test results and clinical management information on subjects who undergo EC/EG to assess for the presence of BE/EAC. Once sufficient time has elapsed for EsoGuard results to be available, as well as for any subsequent clinical evaluation to have been performed (e.g., upper endoscopy and any initial therapeutic management), study staff will obtain the desired information and record it in an electronic data collection (EDC) system, pertaining to subject demographics, pertinent medical history, and risk factors for BE or EAC as well as (1) information about the EsoCheck cell collection procedure and patient tolerance, (2) EsoGuard test result; (3) initial clinical management including upper endoscopy, if performed, and diagnosis (as determined by the endoscopist and the pathologist assessing any biopsies taken.
For subjects endoscopically confirmed with intestinal metaplasia, dysplasia, or cancer, the registry will collect additional clinical management and/or a therapeutic procedure(s) performed and other mid- to long-term outcomes.
For subjects who are negative for BE/EAC via EsoGuard or negative for BE/EAC via EGD will be offered the option of longer-term follow-up in the form of intermittent wellness checks.
The time point for collecting such information shall be fluid, depending on the time course of care provided subsequent to the EsoGuard result being available. Subject participation duration is dependent on EsoGuard results, physician referral, EGD results (if referred) and participation in long-term follow-up. If EG results are negative and subject is not referred for an EGD, participation could last 1 month. If a subject is confirmed with BE/EAC, participation may continue beyond this minimum for an indefinite period, with no predetermined maximum duration.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Study Project Manager
- Telefonnummer: 917-813-1828
- E-mail: axr@pavmed.com
Undersøgelse Kontakt Backup
- Navn: Sr. Director
- E-mail: gxl@pavmed.com
Studiesteder
-
-
California
-
Lake Forest, California, Forenede Stater, 92630
- Rekruttering
- LUCID DX
-
Kontakt:
- Lucid Dx Labs
- Telefonnummer: 888-582-4339
- E-mail: info@LucidDx.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Subjects who have recently undergone or are scheduled to undergo EsoCheck administration (as prescribed by a licensed healthcare provider) will be invited to participate in the optional EsoGuard Registry.
Beskrivelse
Inclusion Criteria:
- Individuals in whom a healthcare provider has made the independent clinical decision to screen for BE/EAC (based on assessment of elevated disease risk) using EsoGuard for analysis of cell samples collected with EsoCheck
- Provided written informed consent for prospective registry participation/data collection
Exclusion Criteria:
- Inability to provide written informed consent
- Subjects who fall outside the eligible population defined by the EsoCheck device Instructions For Use (IFU)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Subsequent Clinical Management Following EsoGuard Testing
Tidsramme: Up to 12 months following EsoGuard testing
|
Proportion of subjects who undergo a clinically relevant management action following receipt of an EsoGuard result, including referral for esophagogastroduodenoscopy (EGD), surveillance, therapeutic intervention, or other physician-directed management. Clinical management decisions are collected as part of routine clinical care. |
Up to 12 months following EsoGuard testing
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Endoscopic Confirmation of Barrett's Esophagus and/or Esophageal Neoplasia
Tidsramme: Up to 12 months following EsoGuard testing
|
Proportion of subjects with a completed EGD and pathology assessment confirming Barrett's esophagus (BE), dysplasia, esophageal adenocarcinoma (EAC), or other relevant esophageal findings following EsoGuard testing. |
Up to 12 months following EsoGuard testing
|
|
Disease Stage at Endoscopic Diagnosis
Tidsramme: Up to 12 months following EsoGuard testing
|
Histologic and/or clinical stage of Barrett's esophagus, dysplasia, or esophageal neoplasia identified during clinically indicated endoscopic evaluation following EsoGuard testing. |
Up to 12 months following EsoGuard testing
|
|
Therapeutic Interventions Following EsoGuard Testing
Tidsramme: Up to 12 months following EsoGuard testing
|
Proportion of subjects who undergo therapeutic intervention for BE, dysplasia, or EAC, including endoscopic eradication therapy, surgical intervention, pharmacologic treatment, or other standard-of-care management. |
Up to 12 months following EsoGuard testing
|
|
Surveillance Utilization Following EsoGuard Testing
Tidsramme: Up to 24 months following EsoGuard testing
|
Proportion of subjects who undergo follow-up surveillance procedures or monitoring for BE/EAC according to routine clinical practice. |
Up to 24 months following EsoGuard testing
|
|
Incident Detection of Barrett's Esophagus or Esophageal Adenocarcinoma
Tidsramme: Up to 24 months following EsoGuard testing
|
Number and proportion of subjects initially considered negative for BE/EAC who subsequently receive a diagnosis of BE, dysplasia, or EAC during follow-up. |
Up to 24 months following EsoGuard testing
|
|
Disease Progression or Resolution
Tidsramme: Up to 24 months following EsoGuard testing
|
Among subjects with identified esophageal disease, assessment of disease progression, stability, or resolution based on available endoscopic, histologic, and clinical follow-up data. |
Up to 24 months following EsoGuard testing
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studiestol: Victoria Lee, MD, Lucid Diagnostics
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- LUD-PR-0421
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .